Matthew Monberg

2.0k total citations
79 papers, 1.4k citations indexed

About

Matthew Monberg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Matthew Monberg has authored 79 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 41 papers in Pulmonary and Respiratory Medicine and 19 papers in Reproductive Medicine. Recurrent topics in Matthew Monberg's work include Lung Cancer Treatments and Mutations (32 papers), Ovarian cancer diagnosis and treatment (19 papers) and Lung Cancer Research Studies (19 papers). Matthew Monberg is often cited by papers focused on Lung Cancer Treatments and Mutations (32 papers), Ovarian cancer diagnosis and treatment (19 papers) and Lung Cancer Research Studies (19 papers). Matthew Monberg collaborates with scholars based in United States, United Kingdom and Italy. Matthew Monberg's co-authors include Coleman K. Obasaju, Zhishen Ye, Chandra P. Belani, Hedy L. Kindler, Pasi A. Jänne, David M. Mintzer, Mark A. Socinski, Joseph S. Friedberg, Nicholas J. Vogelzang and David J. Sugarbaker and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Matthew Monberg

70 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Monberg United States	19	1.0k	539	195	188	146	79	1.4k
Antonia Strippoli Italy	17	438 0.4×	532 1.0×	328 1.7×	134 0.7×	46 0.3×	66	1.1k
Christine Rebischung France	16	416 0.4×	570 1.1×	362 1.9×	125 0.7×	58 0.4×	34	935
Amelia Insa Spain	18	697 0.7×	1.1k 2.0×	112 0.6×	317 1.7×	68 0.5×	63	1.5k
Pasquale Comella Italy	17	780 0.8×	1.2k 2.2×	180 0.9×	249 1.3×	175 1.2×	55	1.6k
Marcos V. Perini Australia	18	336 0.3×	477 0.9×	567 2.9×	106 0.6×	52 0.4×	97	1.2k
C. Sternberg Italy	16	606 0.6×	397 0.7×	225 1.2×	210 1.1×	143 1.0×	67	1.1k
Muriel Debois Belgium	19	907 0.9×	810 1.5×	306 1.6×	148 0.8×	143 1.0×	39	1.6k
Paolo Alessandroni Italy	17	457 0.5×	778 1.4×	386 2.0×	112 0.6×	42 0.3×	37	1.2k
Yoh Isobe Japan	16	1.2k 1.2×	434 0.8×	827 4.2×	181 1.0×	64 0.4×	38	1.7k
Hans J.M. Smit Netherlands	20	1.3k 1.3×	950 1.8×	269 1.4×	164 0.9×	98 0.7×	56	1.7k

Countries citing papers authored by Matthew Monberg

Since Specialization

Citations

This map shows the geographic impact of Matthew Monberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Monberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Monberg more than expected).

Fields of papers citing papers by Matthew Monberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Monberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Monberg. The network helps show where Matthew Monberg may publish in the future.

Co-authorship network of co-authors of Matthew Monberg

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Monberg. A scholar is included among the top collaborators of Matthew Monberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Monberg. Matthew Monberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mukherjee, Amrita, Lanfang Xu, Kimberly L. Cannavale, et al.. (2025). Clinical Remission Rates in Patients With Epithelial Ovarian Cancer Before and After the Onset of the COVID 19 Pandemic in an Integrated Healthcare Delivery System. Cancer Management and Research. Volume 17. 281–291.

Monk, Bradley J., et al.. (2024). Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States. Oncology and Therapy. 13(1). 85–98. 5 indexed citations

Melamed, Alexander, et al.. (2024). Patterns of use of primary and first-line chemotherapy for recurrence among patients with cervical cancer. International Journal of Gynecological Cancer. 34(7). 1001–1010. 1 indexed citations

Monberg, Matthew, Vassiliki Karantza, Konstantinos Tryfonidis, et al.. (2024). A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers. Oncology and Therapy. 12(4). 701–734. 1 indexed citations

Monberg, Matthew, et al.. (2023). Relative and functioning sleep disturbance and fatigue: Impact on patients with ovarian cancer.. Journal of Clinical Oncology. 41(16_suppl). e24102–e24102.

Chen, Ling, et al.. (2022). Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer. Archives of Gynecology and Obstetrics. 305(6). 1647–1654.

Stone, Rebecca L., et al.. (2021). Patients’ and oncologists’ preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer. Future Oncology. 18(4). 491–503. 4 indexed citations

Monberg, Matthew, et al.. (2014). Economic Cost of Adverse Events Per Course of Therapy with Commonly Used First-Line Regimens for the Treatment of Chronic Lymphocytic Leukemia. Value in Health. 17(3). A79–A79. 2 indexed citations

Ortuzar, Waldo, Nasser H. Hanna, Eduardo J. Pennella, et al.. (2011). Brain Metastases as the Primary Site of Relapse in Two Randomized Phase III Pemetrexed Trials in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 13(1). 24–30. 24 indexed citations

10.

Obasaju, Coleman K., Rafat Ansari, Mark A. Socinski, et al.. (2010). A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(7). 993–1000. 7 indexed citations

11.

Movsas, Benjamin, Corey J. Langer, Helen J. Ross, et al.. (2010). Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(5). 673–679. 14 indexed citations

12.

Zinner, Ralph, Scott Saxman, Guangbin Peng, Matthew Monberg, & Waldo Ortuzar. (2010). Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non–Small-Cell Lung Cancer of Nonsquamous Histology. Clinical Lung Cancer. 11(5). 352–357. 13 indexed citations

13.

Rivera, M. Patricia, Frank C. Detterbeck, Mark A. Socinski, et al.. (2009). Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer. CHEST Journal. 135(6). 1588–1595. 27 indexed citations

14.

Detterbeck, Frank C., Mark A. Socinski, Richard J. Gralla, et al.. (2008). Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(1). 37–45. 21 indexed citations

15.

Dudek, Arkadiusz Z., Timothy Larson, Michael McCleod, et al.. (2008). Phase 1/2 Dose Escalating Study of Twice-Monthly Pemetrexed and Gemcitabine in Patients with Advanced Cancer and Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(4). 394–399. 16 indexed citations

16.

Kulkarni, Pandurang M., Ruqin Chen, Taruna Anand, Matthew Monberg, & Coleman K. Obasaju. (2008). Efficacy and safety of pemetrexed in elderly cancer patients: Results of an integrated analysis. Critical Reviews in Oncology/Hematology. 67(1). 64–70. 7 indexed citations

17.

Movsas, Benjamin, Corey J. Langer, Robert M. Jotte, et al.. (2007). P2-195: Phase 2 trial of cisplatin (C), etoposide (E), and radiation (RT) followed by gemcitabine (G) vs G and docetaxel (D) in stage III A/B unresectable non-small-cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S648–S648.

18.

Jänne, Pasi A., Antoinette J. Wozniak, Chandra P. Belani, et al.. (2006). Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program. Journal of Thoracic Oncology. 1(6). 506–512. 50 indexed citations

19.

Masters, Gregory A., Athanassios Argiris, Elizabeth A. Hahn, et al.. (2006). A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 1(1). 19–24. 1 indexed citations

20.

Obasaju, Coleman K., Zhishen Ye, L. P. Bloss, Matthew Monberg, & Rafael E. Curiel. (2005). Gemcitabine/Carboplatin in Patients with Metastatic Non–Small-Cell Lung Cancer: Phase II Study of 28-Day and 21-Day Schedules. Clinical Lung Cancer. 7(3). 202–207. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact